Sjællands Universitetshospital
- Address
- lock Available on a paid plan
Sjællands Universitetshospital - Oncology and Cardiovascular Research Center
Sjællands Universitetshospital is a leading Danish research institution conducting innovative clinical trials across multiple therapeutic areas. The center demonstrates particular expertise in hematologic malignancies and cardiovascular disorders, with a focus on advancing treatment strategies for complex patient populations requiring specialized care.
- Chronic Lymphocytic Leukemia (CLL) - investigating novel combination regimens with targeted therapies including venetoclax and obinutuzumab for previously untreated patients with coexisting medical conditions
- Cutaneous malignancies - optimizing electrochemotherapy protocols through dose-reduction studies of bleomycin while maintaining therapeutic efficacy
- Non-obstructive hypertrophic cardiomyopathy - evaluating pharmacological interventions with beta-blockers and calcium channel blockers to reduce symptomatic burden and arrhythmic complications
The center's research portfolio reflects a commitment to improving outcomes in both oncology and cardiology, with emphasis on personalized treatment approaches. Their trials address critical clinical questions including efficacy optimization in patients with complex comorbidities, dose-finding studies to minimize treatment toxicity, and comparative effectiveness research to guide evidence-based therapeutic decision-making for symptomatic disease management.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Top 2 of 6 therapeutic areas and 15 of 35 IMPs, ranked by number of trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 4 by active trials.
- 1Oslo University Hospital HF1active
lock +3 more on a paid plan
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
No repeated partnerships found.
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 111 other sites in Denmark
Therapeutic Area Benchmark — Denmark
Select a therapeutic area to compare against other sites in Denmark.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: Denmark
Market Share
Country: Denmark
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in Sjællands Universitetshospital
lock Showing 1 of 5 trials — the rest is available on a paid plan.
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| Efficacy and Safety Comparison of Obinutuzumab-Venetoclax vs. Obinutuzumab-Chlorambucil in Untreated CLL with Comorbidities | F. Hoffmann-La Roche AG | Phase III | Not Recruiting | Dec 2014 | Aug 2025 |
IMP list
lock Showing 1 of 35 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| Alteplase | 1 | Unknown | 2025-03-10 | 2025-03-10 |
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.